Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy

Interactions between compound E16 and MMP-2 in a three dimentional stereogram. [Display omitted] •18 Dihydropyrazothiazole derivatives had been synthesized.•Most of the compounds showed low toxicity to 293T/LO2 cells.•Compound E17 showed the most potent and best selective MMP-2 inhibition.•We built...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2018-12, Vol.28 (23-24), p.3816-3821
Hauptverfasser: Wang, Zhong-Chang, Shen, Fa-Qian, Yang, Meng-Ru, You, Ling-Xia, Chen, Li-Zhi, Zhu, Hai-Liang, Lu, Ya-Dong, Kong, Fan-Lei, Wang, Ming-Hua
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Interactions between compound E16 and MMP-2 in a three dimentional stereogram. [Display omitted] •18 Dihydropyrazothiazole derivatives had been synthesized.•Most of the compounds showed low toxicity to 293T/LO2 cells.•Compound E17 showed the most potent and best selective MMP-2 inhibition.•We built a 3D-QASR model for the further explanation of SAR about these compounds. MMP-2/MMP-8 is established as one of the most important metalloenzymes for targeting cancer. A series of dihydropyrazothiazole derivatives (E1–E18) bearing a salicylaldehyde group linked to Pyrazole ring were designed, synthesized, and evaluated for their pharmacological activity as MMP-2/MMP-8 inhibitors. Among them, compound E17 exhibited most potent inhibitory activity (IC50 = 2.80 μM for MMP-2 and IC50 = 5.6 μM for MMP-8), compared to the positive drug CMT-1 (IC50 = 1.29 μM). Compounds (E1–E18) were scrutinized by CoMFA and CoMSIA techniques of Three-dimensional quant. structure-activity relationship (3D-QSAR), as well as a docking simulation. Moreover, treatment with compound E4 could induce MCF-7 cell apoptosis. Overall, the biological profile of E1–E18 may provide a research basis for the development of new agents against cancer.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2018.05.004